Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical
From the article
As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal with Californian medtech Vivani Medical to help.
Continue reading on Fierce BiotechYou might also wanna read

Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies
The Guardian·2d ago

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies
The Guardian·2d ago
Novo Nordisk: Vægttabsmedicin rykker ind i forbrugersegmentet og kan nå 100 mia. dollars i 2030
Novo Nordisks vægttabsmedicin (Wegovy, Ozempic) bevæger sig ind i et forbrugersegment, hvor kunder opfører sig som dagligvareforbrugere snar
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
Bars·1d ago
Novo Nordisk: Wachstum im Diabetes- und Adipositasmarkt – Innovation, Kapazitäten und Pipeline-Fokus
IT BOLTWISE·11h ago
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p

Comments
Sign in to join the conversation.
No comments yet. Be the first.